SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Organovo (ONVO)
ONVO 2.360-12.6%Nov 3 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Glenn Petersen1/14/2014 8:09:08 PM
3 Recommendations

Recommended By
i-node
snookcity
Zen Dollar Round

  Read Replies (1) of 171
 
NIH partners with Organovo to test new drugs on 3D printed living tissue

By Signe Brewster
Gigaom
January 14, 2014

Summary: The partnership will focus on the creation of eye tissue, which can be used for toxicology tests and to study the advancement of diseases.



photo: Organovo
_______________

Every newly developed pharmaceutical drug takes a long, winding path before it is ever administered to a human in a clinical trial. It’s first tested in a petri dish and on animals, which, it turns out, are fairly poor ways to predict how successful a drug will be for a human.

Soon, it will be possible to cut out dishes and animals and instead test drugs directly on living human tissue. San Diego-based Organovo, which develops methods to 3D print living tissue, announced today that it will partner with two National Institutes of Health groups to print tissue for medical purposes.

“Researchers who develop new therapies for patients are too often hampered by animal models and traditional cell culture models that are poor predictors of drug efficacy and toxicity in human beings,” Organovo CEO Keith Murphy said in a release. “Our 3D printer creates living human tissues that more closely reproduce in vivo human tissues.”

Organovo will partner with the National Center for Advancing Translational Sciences and the National Eye Institute. While Organovo is currently working independently on printing and commercializing liver tissue for toxicology testing, both NIH partnerships will focus on printing eye tissue. The tissue will also be used to study disease advancement.

The tissue will be printed on Organovo’s NovoGen MMX Bioprinter. It works much like an ink printer, except that it lays down living cells layer-by-layer. Each new layer is supported by gel, which acts as scaffolding until it can be stripped away at the end of the printing process. Cells can be printed in different structures, such as a tube to create an artery. So far, the company has printed liver tissue, bone, blood vessels, muscle, heart tissue and more.



gigaom.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext